Drugs / Thymosin Alpha
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymosin Alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658692 ↗ |
| Known as | Thymalfasin for Injection | “Thymosin Alpha（Thymalfasin for Injection） 1.6mg subcutaneously twice a week.” NCT05658692 ↗ |